Aurora kinase targeted therapeutics in oncology: Past, present and future

Expert Opinion on Drug Discovery

Volumn 2, Issue 7, 2007, Pages 1011-1026

  Mahadevan, Daruka ^a   Beeck, Sunni ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Aneuploidy; Aurora kinase; Cancer; Cell cycle; Mitotic phase; Small molecular inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; AT 9283; AURORA A KINASE; AURORA A KINASE INHIBITOR; AURORA B KINASE; AURORA B KINASE INHIBITOR; AURORA C PROTEIN; AURORA KINASE INHIBITOR; AZD 1152; CYC 116; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; ENZYME INHIBITOR; JNJ 7706621; MITOXANTRONE; MLN 8054; MONOCLONAL ANTIBODY; MP 235; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PHA 680632; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; PYRIMIDOOXAZEPINE; R 763; SNS 314; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCA ALKALOID; VX 608;

BONE MARROW SUPPRESSION; CANCER; CANCER RISK; CATALYSIS; CENTROSOME; CHROMOSOME CONDENSATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CRYSTAL STRUCTURE; CYTOKINESIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; GENE MUTATION; GENE OVEREXPRESSION; GENETIC CODE; GENETIC RISK; HEMATOLOGIC MALIGNANCY; HUMAN; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SOLID TUMOR;

EID: 34547428431     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.7.1011     Document Type: Review

References (88)

1. CARMENA M, EARNSHAW WC: The cellular geography of Aurora kinases. Nat. Rev. Mol. Cell Biol. (2003) 4:842-854.
2. NIGG EA: Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. (2001) 2:21-32.
3. FRANCISCO L, WANG W, CHAN CS: Type 1 protein phosphotase acts in opposition to Ipl1 protein kinase in regulating yeast chromosome segregation. Mol. Cell Biol. (1994) 14:4731-4740.
4. PETERSEN J, PARIS J, WILLER M et al.: The S. pombe aurora-related kinase Ark1 associates with mitotic structures in a stage dependent manner and is required for chromosome segregation. J. Cell Sci. (2001) 114:4371-4384.
5. BROWN JR, KORETKE KK, BIRKELAND ML et al.: Evolutionary relationships of Aurora kinases: implications for model organism studies and the development of anti-cancer drugs. BMC Evol. Biol. (2004) 4(1):39.
6. GIET R, PRIGENT C: Aurora/Ipl1p-related kinases, a new oncogenic family of mitotic serine-threonine kinases. J. Cell. Sci. (1999) 112( Part 21):3591-3601.
7. MAHADEVAN D, BEARSS D, VANKAYALPATI H: Structure based design of novel anti-cancer agents targeting aurora kinase. Curr. Med. Chem. Anticancer Agents (2003) 3:25-34.
8. GIET R, PRIGENT C: The non-catalytic domain of the Xenopus laevis auoraA kinase localizes the protein to the centrosomes. J. Cell. Sci. (2001) 114(11):2095-2104.
9. LARGAUER C, KINZLER KW, VOGELSTEIN B: Genetic instabilities in human cancers. Nature (1998) 396:643-649.
10. KIMURA M, MATSUDA Y, YOSHIOKA T et al.: Cell cycle-dependent expression and centrosome localization of a third human Aurora/ Ipl1-related protein kinase, AIK3. J. Biol. Chem. (1999) 274:7334-7340.
11. MATTHEWS N, VISINTIN C, HARTZOULAKIS B et al.: Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expert Rev. Anticancer Ther. (2006) 61(1):109-120.
12. KEEN N, TAYLOR S: Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer (2004) 4:927-936.
13. ADAMS RR, CARMENA M, EARNSHAW WC: Chromosomal passengers and the (Aurora) ABC's of mitosis. Trends Cell Biol. (2001) 11:49-54.
14. KUFER TA, NIGG EA, SILLJE HH: Regulation of Aurora-A kinase on the mitotic spindle. Chromosoma (2003) 112(4):159-163.
15. TSAI MY, WIESE C, CAO K et al.: A Ran signaling pathway mediated by the mitotic kinase Aurora A in spindle assembly. Nat. Cell Biol. (2003) 5(3):242-248.
16. HIROTA T, KUNITOKU N, SASAYAMA T et al.: Aurora A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell (2003) 114(5):585-598.
17. GIET R, MCLEAN D, DESCAMPS S et al.: Drosophila Aurora A kinase is required to localize D-TACC to centrosomes and to regulate astral microtubules. J. Cell Biol. (2002) 156(3):437-451.
18. TERADA Y, UETAKE Y, KURIYAMA R: Interaction of Aurora A and centrosomin at the microtubule-nucleating site in Drosophila and mammalian cells. J. Cell Biol. (2003) 162(5):757-763.
19. LIU Q, KANEKO S, YANG L et al.: Aurora A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215. J. Biol. Chem. (2004) 279(50):52175-52182.
20. SAKAI H, URANO T, OOKATA K et al.: MBD3 and HDAC1, two components of the NuRD complex, are localized to Aurora A-positive centrosomes in M phase. J. Biol. Chem. (2002) 277(50):48714-48723.
21. 2 to M transition. J. Biol. Chem. (2004) 279(19):19643-19648.
22. MARUMOTO T, HONDA S, HARA T et al.: Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa Cells. J. Biol. Chem. (2003) 278(51):51786-51795.
23. WALTER AO, SEGHEZZI W, KORVER W et al.: The mitotic serine/ threonine kinase Aurora2/AIK is regulated by phosphorylation and degradation. Oncogene (2000) 19(42):4906-4916.
24. ANAND S, PENRHYN-LOWE S, VENKITARAMAN AR: Aurora-A amplification overrides the mitotic spindle assembly checkpoint including resistance to Taxol. Cancer Cell (2003) 3(1):51-62.
25. MERALDI P, HONDA R, NIGG EA: Aurora-A over-expression reveals tetraploidation as a major route to centrosome amplification in p53-/- cells. EMBO J. (2002) 21:483-492.
26. BOLTON MA, LAN W, POWERS SE et al.: Aurora B kinase exists in a complex with survivin and INCENP and its kinase is stimulated by surviving binding and phosphorylation. Mol. Cell Biol. (2002) 13(9):3064-3077.
27. HONDA R, KORNER R, NIGG EA: Exploring the functional interactions between Aurora B, INCENP and survivin in mitosis. Mol. Biol. Cell (2003) 14(8):3325-3341.
28. GASSMANN R, CARVALHO A, HENZING AJ et al.: Borealin: a novel chromosomal passenger required for stability of the bipolar mitotic spindle. J. Cell Biol. (2004) 166(2):179-191.
29. KALLIO MJ, MCCLELAND ML, STUKENBERG PT, GORBSKY GJ: Inhibition of Aurora B kinase blocks chromosome segregation, overrides the spindle checkpoint, and perturbs microtubule dynamics in mitosis. Curr. Biol. (2002) 11:900-905.
30. HSU JY, SUN ZW, LI X et al.: Mitotic phosphorylation of histone H3 is governed by Ipl1/Aurora kinase and Glc7/PPI phosphatase in budding yeast and nematode. Cell (2000) 102(3):279-291.
31. MORRISON C, HENZING AJ, JENSEN ON et al.: Proteomic analysis of human metaphase chromosomes reveals topoisomerase II α as an Aurora B substrate. Nucleic Acid Res. (2002) 30(23):5318-5327.
32. GOTO H, YASUI Y, KAWAJIRI A et al.: Aurora-B regulates the cleavage furrow-specific vimentin phosphorylation in the cytokinetic process. J. Biol. Chem. (2003) 278(10):8526-8530.
33. GIET R, GLOVER DM: Drosophila Aurora B kinase is required for histone H3 phosphorylation and condensin recruitment during chromosome condensation and to organize the central spindle during cytokinesis. J. Cell Biol. (2001) 152(4):669-682.
34. DITCHFIELD C, JOHNSON VL, TIGHE A et al.: Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J. Cell Biol. (2003) 161(2):267-280.
35. GADEA BB, RUDERMAN JV: Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the establishment of the spindle integrity checkpoint in Xenopus egg extracts. Mol. Biol. Cell (2005) 16(3):1305-1318.
36. TSENG TC, CHEN SH, HSU YP et al.: Protein kinase profile of sperm and eggs: toning and characterization of two novel tests specific protein kinuses (AIE1, AIE2) related to yeast and fly chromosome segregation regulators. DNA Cell Biol. (1998) 17(10):823-833.
37. YAN X, CAO L, LI Q et al.: Aurora C is directly associated with Survivin and required for cytokinesis. Genes Cells (2005) 10(6):617-626.
38. SASAI K, KATAYAMA H, STENOIEN D et al.: Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton (2004) 59(4):249-263.
39. SEN S, ZHOU H, WHITE RA: A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and over-expressed in human breast cancer cell lines. Oncogene (1997) 14(18):2195-2200.
40. BISCHOFF JR, ANDERSON L, ZHU Y et al.: A homologue of Drosophila Aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J. (1998) 17(11):3052-3065.
41. ZHOU H, KUANG J, ZHONG L et al.: Tumor amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet. (1998) 20:189-193.
42. LITTLEPAGE LE, WU H, ANDRESSON T et al.: Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A. Proc. Natl. Acad. Sci. USA (2002) 99(24):15440-15445.
43. EWART-TOLAND A, BRIASSOULI P, DE KONING JP et al.: Identification of stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat. Genet. (2003) 34:403-412.
44. MIAO X, SUN T, WANG Y et al.: Functional STK15 Phe31Ile polymorphism is associated with the occurrence and advanced disease status of esophageal squamous cell carcinoma. Cancer Res. (2004) 64:2680-2683.
45. TATSUKA M, SATO S, KITAJIMA S et al.: Over-expression of Aurora A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene (2005) 24:1122-1127.
46. GIET R, PETRETTI C, PRIGENT C: Aurora kinases, aneuploidy and cancer, a coincidence or a real link? Trends Cell Biol. (2005) 15(5):241-250.
47. OTA T, SUTO S, KATAYAMA H et al.: Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora B over-expression contributes to chromosome number instability. Cancer Res. (2002) 62(8):5168-5177.
48. SMITH SL, BOWERS NL, BETTICHER DC et al.: Overexpression of Aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br. J. Cancer (2005) 93(6):719-729.
49. TAKAHASHI T, FUTAMARA M, YOSHIMI N et al.: Centrosomal kinases, HsAIRK1 and HsAIRK3, are overexpressed in primary colorectal cancers. Jpn. J. Cancer Res. (2000) 91(10):1007-1014.
50. NARUGANAHALLI KS, LAKSHMANAM M, DASTIDAR SG, RAY A: Therapeutic potential of Aurora kinase inhibitors in cancer. Curr. Opin. Investig. Drugs (2006) 12:1044-1051.
51. GOLD MG, BARFORD D, KOMANDER D: Lining the pockets of kinases and phosphatases. Curr. Opin. Struct. Biol. (2006) 6:693-701.
52. FU S, HU W, KAVANAGH JJ et al.: Targeting Aurora kinases in ovarian cancer. Expert Opin. Ther. Targets (2006) 10(1):77-85.
53. BOLANOS-GARCIA VM: Aurora kinases. Int. J. Biochem. Cell Biol. (2005) 8:1572-1577.
54. MORTLOCK AA, KEEN NJ, JUNG FH et al.: Progress in the development of selective inhibitors of Aurora kinases. Curr. Top. Med. Chem. (2005) 5:807-821.
55. GAUTSHI O, MACK PC, DAVIES AM et al.: Aurora kinase inhibitors: a new class of targeted drugs in cancer. Clin. Lung Cancer (2006) 8(2):93-98.
56. GIRDLER F, GASCOIGNE KE, EYERS PA et al.: Validating Aurora B as an anti-cancer drug target. J. Cell Sci. (2006) 119:3664-3675.
57. WARNER SL, MUNOZ RM, STAFFORD P et al.: Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells. Mol. Cancer Ther. (2006) 5(10):2450-2458.
58. HAUF S, COLE RW, LATERRA S et al.: The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore microtubule attachment and in maintaining the spindle assembly checkpoint. J. Cell Biol. (2003) 161:281-294.
59. HARRINGTON EA, BEBBINGTON D, MOORE J et al.: VX-680, a potent and selective small-molecular inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. (2004) 10(3):262-267.
60. MARGOLIS RL, LOHEZ OD, ANDREASSEN PR: G1 tetraploidy checkpoint and the suppression of tumorigenesis. J. Cell. Biochem. (2003) 88:673-683.
61. TANAKATU, RACHIDI N, JANKE C et al.: Evidence that the Ipl1-Sli15 (Aurora kinase-INCENP) complex promotes bi-orientation by altering kinerochore-spindle pole correctors. Cell (2002) 108:317-329.
62. YANG H, BURKET, DEMPSEY J et al.: Mitotic requirement for Aurora A kinase is bypassed in the absence of Aurora B kinase. FEBS Lett. (2005) 579(16):3385-3391.
63. JUNG FH, PASQUET G, LAMBERT-VAN DER BREMPT C et al.: Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors. J. Med. Chem. (2006) 49:955-970.
64. FANCELLI D, BERTA D, BINDI S et al.: Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J. Med. Chem. (2005) 48(8):3080-3084.
65. SONCINI C, CARPINELLI P, GIANELLINI L et al.: PHA-680632, a novel Aurora kinase inhibitor with potent anti-tumoral activity. Clin. Cancer Res. (2006) 12(13):4080-4089.
66. EMANUEL S, RUGG CA, GRUNINGER RH et al.: The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and Aurora kinases. Cancer Res. (2005) 65(19):9038-9046.
67. MANFREDI MG, ECSEDY JA, MEETZE KA et al.: Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc. Natl. Acad. Sci. USA (2007) 104(10):4106-4111.
68. PAN W, LIU H, XU Y-J et al.: Pyrimido-oxazepine as a versatile template for the development of inhibitors of specific kinases. Bioorg. Med. Chem. Lett. (2005) 15:5474-5477.
69. WARNER SL, BASHYAM S, VANKAYLAPATI H et al.: Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach. Mol. Cancer Ther. (2006) 5(7):1764-1773.
70. VANKAYALAPATI H, ROJANALA S, SALDANHA J et al.: Targeting Aurora kinase 2 in oncogenesis: a structural bioinformatics approach to target validation and rational drug design. Mol. Cancer Ther. (2003) 3:283-294.
71. GILL A, CLEASBY A, JHOTI H: The discovery of novel protein kinase inhibitors by using fragment-based high-throughput X-ray crystallography. ChemBioChem (2005) 6:506-512.
72. GILES FJ, CORTES J, JONES D et al.: MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood (2007) 109(2):500-502.
73. YOUNG MA, SHAH NP, CHAO LH et al.: Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. (2006) 66:1007-1014.
74. CHEETHAM GM, KNEGTEL RM, COLL JT et al.: Crystal structure of Aurora-2, an oncogenic serine/threonine kinase. J. Biol. Chem. (2002) 277(45):42419-42422.
75. NOWAKOWSKI J, CRONIN CN, MCREE DE et al.: Structures of the cancer-related Aurora-A, FAK and EphA2 protein kinases from nanovolume crystallography. Structure (2002) 10(12):1659-1667.
76. BAYLISS R, SARDON T, VERNOS I et al.: Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol. Cell (2003) 12(4):851-862.
77. HERON NM, ANDERSON M, BOWERS DP et al.: SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors. Bioorg. Med. Chem. Lett. (2005) 16:1320-1323.
78. WANG Z, CANAGARAJAH BJ, BOEHM JC et al.: Structural basis of inhibitor selectivity in MAPKs. Structure (1998) 6(9):1117-1128.
79. SESSA F., MAPELLI M, CIFERRI C et al.: Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. Mol. Cell (2005) 18(3):379-391.
80. HUSE M, KURIYAN J: The conformational plasticity of protein kinases. Cell (2002) 109:275-282.
81. GREENMAN C, STEPHANS P, SMITH R et al.: Patterns of somatic mutations in human cancer genomes. Nature (2007) 446:153-158.
82. CARVAJAL RD, TSE A, SSHWARTZ GK: Aurora kinases: new targets for cancer therapy. Clin. Cancer Res. (2006) 12(23):6869-6875.
83. DANCEY JE, CHEN HX: Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat. Rev. Drug Discov. (2006) 5(8):649-659.
84. FANCELLI D, MOLL J, VARASI M et al.: 1,4,5,6-Tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J. Med. Chem. (2006) 49:7247-7251.
85. SEAMON JA, RUGG CA, EMANUEL S et al.: Role of the ABCG2 drug transporter in the resistance and oral bioavailability of a potent cyclin-dependent/Aurora kinase inhibitor. Mol. Cancer Ther. (2006) 5(10):2459-2467.
86. HANAHAN D, WEINBERG PA: The hallmarks of cancer. Cell (2000) 100(1):57.
87. SUN C, CHAN F, BRIASSOULI P, LINARDOPOULOS S: Aurora kinase inhibition downregulates NF-κB and sensitises tumour cells to chemotherapeutic agents. Biochem. Biophys. Res. Commun. (2007) 352(1):220-225.
88. TARI LW, HOFFMAN ID, BENSEN DC et al.: Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors To be published as per PDB (2006).